Questions over dual use and whether menthol flavours would attract at-risk groups led the start of the long-awaited Food and Drug Administration (FDA) hearing for Philip Morris International (PMI)’s modified risk claim for its IQOS heated-tobacco product ...
Restricted content. Do you want to read more?
Register
Sign up NOW for 7 days FREE TRIAL and access our briefings section
